ETESIAN: A phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia

Saved in:

Bibliographic Details
Published in	Atherosclerosis Vol. 355; p. 28
Main Authors	Hofherr, A., Schumi, J., Rekić, D., Knöchel, J., Nilsson, C.A.M., Rudvik, A., Hurt-Camejo, E., Wernevik, L., Rydén-Bergsten, T., Koren, M., Carlsson, B.C.L.
Format	Journal Article
Language	English
Published	Elsevier B.V 01.08.2022
Online Access	Get full text

Loading…

More Information
ISSN:	0021-9150 1879-1484
DOI:	10.1016/j.atherosclerosis.2022.06.075